Navigation Links
Escalon(R) Reports Financial Results for 2007 Fiscal Year

WAYNE, Pa., Sept. 28 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced results for its fiscal fourth quarter and twelve months ended June 30, 2007.

For the fiscal year 2007, the Company's reported net revenue increased to $38,837,780 compared with $29,790,698 in fiscal 2006. This increase in net revenue was primarily due to a $9.6 million lump sum settlement payment from IntraLase Corp. to the Company. This increase also included product revenue of $27,892,738 for fiscal 2007, compared with $27,543,785 in the prior year. The product revenue increase was primarily related to strong sales in the Company's Sonomed and Escalon Digital Solutions ("EMI") business units, which increased approximately 27.0% and 241.9%, respectively.

This strong growth was offset by an 18.4% decrease in revenues at the Company's Drew business unit primarily due to the non-renewal of two OEM agreements and a temporary delay in the introduction of Drew's new line of products in fiscal 2007. As previously announced, in July 2007, Drew received 510(k) clearance from the FDA to market the new TRILOGY Analyzer. TRILOGY, a multifunction analyzer used in determination of analytes in body fluids, is an open system intended for clinical use with various chemistry assays in professional settings. Additionally, Drew anticipates receiving approval on its new D3 Analyzer in the second quarter of fiscal 2008, which will provide two new enhanced instruments for sale during the year. Further, Drew anticipates submitting its new DS-360 Analyzer for FDA approval in the second half of fiscal 2008.

The Company reported fiscal 2007 net income of $5,914,603, or $0.92 per diluted share, compared with a net loss of ($1,985,940), or ($0.32) per diluted share, in fiscal 2006. This increase was primarily due to increased royalties from the IntraLase License Agreement and the lump sum settlement payment from IntraLase Corp. to the Company, which was recorded during the third quarter of fiscal 2007. The settlement also marked the end of any future royalty payments to be received under the License Agreement, which is expected to have a material effect on earnings in subsequent periods.

For the fourth quarter of fiscal 2007, the Company reported net revenue of $7,474,120, an 3.7% increase from the $7,207,780, reported in the prior year period. This growth was offset by a decrease in the Company's Drew business unit.

Product revenue increased approximately 11.5% to $7,414,831 for the three- month period ended June 30, 2007, compared with $6,648,232 for the same period last fiscal year. For the fourth quarter of fiscal 2007, the Company reported a net loss of ($1,172,639), or ($0.18) per diluted share, compared with a net loss of ($1,142,261), or ($0.19) per diluted share, in the fourth quarter of fiscal 2006

2007 Recap

"I am pleased to be report another successful year for Escalon Medical. Overall, our Sonomed business had an excellent fiscal 2007 driven by increased sales of the new VuMax high frequency systems and the EZ AB scan ultrasound systems. Additionally, we are pleased that EMI's expanding product offering has seen significant market acceptance during the year, which has driven an increase in digital imaging system sales," said Richard J. DePiano, Chairman and Chief Executive Officer.

"Despite the sales decline within our Vascular business unit due to the termination of several distributor relationships during fiscal 2005 and 2006, the unit's profitability has increased due to efforts to replace the impacted territories with direct sales. Moving ahead, we look forward to capitalizing on recent Vascular R&D initiatives and bringing new visual products to market during 2008," Mr. DePiano added.

Mr. DePiano concluded, "Furthermore, with the previously announced reorganization of the Drew business, we have significantly reduced operating costs and expanded operating margins for the Company as a whole. We continue to pursue the significant opportunities ahead and, due to our recent rationalization efforts and anticipated new product launches within Drew and other business units, we enter 2008 with solid momentum and a stronger business platform."

Non-GAAP Measures

To supplement the Company's consolidated financial statements presented in accordance with GAAP, the Company has begun providing certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP net loss and non-GAAP loss per fully diluted share.

The Company's reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards, but are not a substitute for, nor superior to, GAAP results. These non-GAAP measures are provided to enhance investors overall understanding of the Company's current financial performance and provide further information for comparative purposes due to the adoption of the new accounting standard FAS 123R.

Specifically, the Company believes the non-GAAP measures provide useful information to both management and investors by isolating certain expenses, gains and losses that may not be indicative of its core operating results and business outlook. In addition, the Company believes non-GAAP measures that exclude stock-based compensation expense enhance the comparability of results against prior periods. The non-GAAP measures and the reconciliation to the most directly comparable GAAP measure of all non-GAAP measures are as follows:

June 30, June 30, June 30,

2007 2006 2005

Net Income (Loss) $5,914,603 $(1,985,940) $2,448,111

Non-GAAP adjustments:

Stock based compensation $162,576 $- $-

Depreciation and amortization $590,846 $440,952 $387,651

Total adjustments $753,422 $440,952 $387,651

Non-GAAP adjusted income (loss) $6,668,025 $(1,544,988) $2,835,762

Shares used in computing fully

diluted earnings per share 6,434,275 6,152,455 6,231,024

Non-GAAP adjusted income (loss) per

fully diluted share $1.04 $(0.25) $0.46

Founded in 1987, Escalon develops markets and distributes ophthalmic diagnostic and surgical products as well as vascular access devices. Drew, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of Escalon's distribution capabilities. Escalon has headquarters in Wayne, Pennsylvania and manufacturing operations in Long Island, New York, New Berlin, Wisconsin, Dallas, Texas, Oxford, Connecticut and Barrow-in-Furness, U.K.

Note: This press release contains statements that are considered forward- looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. They are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to implement its growth and marketing strategies, improve upon the operations of the Company's business units, including the integration of Drew's and MRP's operations and any acquisitions it may undertake, if any, of which there can be no assurance, implement cost reductions, generate cash and identify, finance and enter into business relationships and acquisitions, uncertainties and risks related to new product development, commercialization, manufacturing and market acceptance of new products, marketing acceptance of existing products in new markets, the continuity of royalty revenue, litigation and non-recurring expenses, research and development activities, including failure to demonstrate clinical efficacy, delays by regulatory authorities, scientific and technical advances by Escalon or third parties, introduction of competitive products, third party reimbursement and physician training as well as general economic conditions. Further information about these and other relevant risks and uncertainties may be found in the Company's report on Form 10- K, and its other filings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.




Three Months Ended June 30, Year Ended June 30,

2007 2006 2007 2006

Net revenues:

Product revenue $7,414,831 $6,648,232 $27,892,738 $27,543,785

Other revenue $59,289 $559,548 $10,945,042 $2,246,913

Revenues, net $7,474,120 $7,207,780 $38,837,780 $29,790,698

Costs and expenses:

Cost of goods sold $4,226,375 $3,993,252 $15,771,254 $16,003,904

Marketing, general

and administrative $3,744,306 $3,599,176 $13,806,399 $13,994,788

Research and

development $822,909 $692,246 $3,461,322 $2,828,196

Total costs and

expenses $8,793,590 $8,284,674 $33,038,975 $32,826,888

(Loss) income from

operations $(1,319,470) $(1,076,894) $5,798,805 $(3,036,190)

Other income and


Gain on sale of

available for sale

securities $75,000 $- $75,000 $1,157,336

Equity in Ocular


Management, LLC $(31,963) $(103,872) $(87,852) $(173,844)

Interest income $95,072 $49,890 $208,457 $161,588

Interest expense $(5,138) $(16,100) $(28,753) $(63,521)

Total other income

and (expense) $132,971 $(70,082) $166,852 $1,081,559

Net (loss) income

before taxes $(1,186,499) $(1,146,976) $5,965,657 $(1,954,631)

Provision for income

taxes $(13,860) $(4,715) $51,054 $31,309

Net (loss) income $(1,172,639) $(1,142,261) $5,914,603 $(1,985,940)

Basic net (loss)

income per share $(0.18) $(0.19) $0.93 $(0.32)

Diluted net (loss)

income per share $(0.18) $(0.19) $0.92 $(0.32)

Weighted average

shares - basic 6,374,929 6,152,455 6,374,929 6,152,455

Weighted average

shares - diluted 6,434,275 6,152,455 6,434,275 6,152,455


June 30, June 30,

2007 2006

Cash, cash equivalents and Investments $8,879,462 $3,429,930

Total current assets $21,763,012 $14,911,249

Total assets $45,017,213 $38,644,767

Current liabilities $4,524,607 $4,295,109

Long-term debt $- $162,551

Total shareholders' equity $39,405,606 $33,100,107

SOURCE Escalon Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
(Date:10/9/2015)... Beach, CA (PRWEB) , ... October 09, 2015 ... ... is now offering a special promotion on Invisalign, the orthodontic system that uses ... reasons. The aligners are almost invisible against the teeth, which allow patients to ...
(Date:10/9/2015)... ... October 09, 2015 , ... On Saturday, September 26, ... Jump Rope Championship in Madrid, Spain. Representing both the USA and Sweden in the ... Unders and One-Minute Am Front Crosses, she was awarded 1 Silver and 4 Gold ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... New Orleans and the surrounding communities, is initiating a combined charity effort with ... for unwanted animals in southern Louisiana. , Animal Rescue New Orleans is ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... upcoming episode of Innovations with Ed Begley Jr., airing 1st QT 2016 via ... will educate audiences on MMJ Phytotech Limited (MMJ) – a global leader in ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... oldest and largest recreational dispensaries in Colorado, says the latest figures on the ... rapidly and maturing into a legitimate industry. , Last month, according to ...
Breaking Medicine News(10 mins):
... of Medicine (BUSM) have found that some medical inpatients ... intervention. The BUSM study appears in the May issue ... . , "Brief intervention shows promise for increasing receipt ... cognitive functioning or an alcohol- attributable diagnosis," said lead ...
... on human genome , , THURSDAY, April 23 (HealthDay News) -- ... has succeeded in sequencing the entire genome of the placid, ... biology of this bovine and related creatures (even humans), and ... two reports in the April 24 issue of Science ...
... Harvard Medical School today announced the launch ... cancer and other prostate conditions understand the issues related ... treatment. The website, , was ... medical oncology and urologic cancer. This website is especially ...
... Keeping Michigan Workers Working!LANSING, Mich., April 23 May ... MICHIGAN will hold a summit involving 120 of Michigan,s ... Workability in Michigan, , ... professions and organizations who are passionate about promoting safer, ...
... MR procedure that uses diffusion-weighted imaging (DWI) to determine ... benign may help reduce unnecessary breast biopsies, according to ... in Bethesda, MD. DWI is a method that produces ... compartments (diffusion). , The study included 80 patients ...
... tubo ovarian abscesses help women avoid surgery, according to ... MA. Tubo ovarian abscesses (TOAs) are an infected collection ... They can occur in patients with complicated cases of ... study included 54 TOAs in 46 patients. Results showed ...
Cached Medicine News:
(Date:10/8/2015)... , Oct. 8, 2015  Ardelyx, Inc. (NASDAQ: ... on gastrointestinal and cardio-renal diseases, today announced that ... tenapanor, will be presented at the 2015 American ... will include measures of sustained response in IBS-C ... placebo-controlled, randomized Phase 2 trial. The meeting will ...
(Date:10/8/2015)... 2015  Trovagene, Inc., (NASDAQ:   TROV) a ... presentation of results from a field experience analysis ... SM (PCM) platform to accurately identify mutational ... determine appropriate therapy for patients. Mark Erlander ... delivering the results today in an oral presentation ...
(Date:10/8/2015)... 2015  Following months of investigation, Ross Feller Casey ... alleging that the anticoagulant Xarelto,s recommended dosage doesn,t work for ... Philadelphia on behalf of a ... the drug didn,t work as the manufacturer suggested. Ross ... shortly on behalf of clients from across the country with ...
Breaking Medicine Technology:
... CLARA, Calif., Oct. 7, 2011 ProteinSimple today ... and field service support for its biologics products ... product lines are included in this expanded support ... Micro-Flow Imaging systems. The biologics market ...
... (Nasdaq: CPHD ) today announced that it will ... 30, 2011, on Thursday, October 20, 2011, after the close ... management presentation at 2 p.m. Pacific Time on Thursday, October ... webcast, please visit Cepheid,s website at at ...
Cached Medicine Technology:
The MACS VA_500 (variable atmosphere) is primarily for the study and isolation of microaerophilic organisms,including Campylobacter spp,Helicobacter pylori and other similarly fastdious organisms....
... an electrical power supply, MERKUR offers a broad ... a gas spring for ease of operation. For ... a foot pedal hydraulic system. Thanks to its ... anytime in a highly mobile and flexible manner. ...
... The operating table MARS Enduro ... examinations or interventions are required before, ... Due to the motorised longitudinal adjustment ... provides optimum working conditions in examination, ...
... Exclusive, 210° Top Rotation provides uncommon ... surgery. The Hercules 6700B eliminates any ... head-end procedures, while providing ample leg ... sit during procedures. Removable back and ...
Medicine Products: